Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
EMA starts review of Xtandi in hormone-sensitive prostate cancerThe EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug Share XEMA starts review of Xtandi in hormone-sensitive prostate cancerhttps://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
Prostate drug approved for use in non-metastatic casesThe US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic Share XProstate drug approved for use in non-metastatic caseshttps://pharmaphorum.com/news/prostate-drug-approved-for-use-in-non-metastatic-cases/
Pfizer confirms $14bn Medivation mergerDrug giant confirms press reports. Share XPfizer confirms $14bn Medivation mergerhttps://pharmaphorum.com/news/pfizer-confirms-14bn-medivation-merger/
